IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.

Other languages ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Equities

1541

CNE100006624

Delayed Hong Kong S.E. Other stock markets 23:50:12 2024-06-25 EDT			5-day change	1st Jan Change
13.92 ^HKD	-0.57%		-1.69%	-53.44%

06-24	ImmuneOnco Biopharmaceuticals Gets IND Approval for NMOSDs Drug Trial in China	MT
06-03	ImmuneOnco Biopharmaceuticals Gets China's Phase 3 Trial Approval for Leukemia Drug	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ImmuneOnco Biopharmaceuticals Gets IND Approval for NMOSDs Drug Trial in China	06-24
ImmuneOnco Completes Filing with China Regulator for Conversion of H Shares	05-30
ImmuneOnco Biopharmaceuticals Inc. Approves the Appointment of Guan Mei as Executive Director	05-28
Immuneonco Biopharmaceuticals Gets Regulatory Go-Ahead for Phase 3 Trial of Myelodysplastic Syndrome Drug in China	05-17
Immuneonco Biopharmaceuticals Inc. Receives Approval from the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China for A Randomized, Double-Blind, Controlled Phase III Clinical Trial of MM01 (Timdarpacept) in Combination with Azacitidine for the First-Line Treatment of Higher-Risk Myelodysplastic Syndrome (HR MDS)	05-17
ImmuneOnco Biopharmaceuticals Inc. Receives Approval from the National Medical Products Administration of the People's Republic of China for the Protocol of the Phase Iii Clinical Trial of IMM01	04-17
Immuneonco Biopharmaceuticals' 2023 Loss Narrows as Other Income Increases	03-26
ImmuneOnco Biopharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-25
Immuneonco Biopharmaceuticals CFO Resigns	03-03
Immuneonco Biopharmaceuticals Inc. Announces Board and Executive Changes	03-01
ImmuneOnco Biopharmaceuticals Inc. Announces First Patient Dosed in the Phase II Clinical Trial of IMM2510 for the Treatment of Refractory or Relapsed Alveolar Soft Part Sarcoma	11-19
ImmuneOnco Biopharmaceuticals Inc. Receives an Investigational New Drug Approval from the National Medical Products Administration of the People's Republic of China	11-07
ImmuneOnco Biopharmaceuticals Inc. Obtains an Investigational New Drug Approval for IMM47 for the Treatment of Solid Tumors from the National Medical Products Administration of the People's Republic of China	23-10-16
Immuneonco Biopharmaceuticals Inc. Provides Updates on the Clinical Trial of Imm47	23-09-27
ImmuneOnco Biopharmaceuticals Inc. Provides Updates on the Clinical Trials of IMM2510 and IMM27M	23-09-11
Hong Kong Stocks Retreat On Fears Over China Property Default; ImmuneOnco Biopharmaceuticals Gains 5%	23-09-05
ImmuneOnco Biopharmaceuticals Inc. has completed an IPO in the amount of HKD 318.93792 million.	23-09-04

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Stock Market
Equities
1541 Stock
News ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Other languages

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer